Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Amortization of Deferred Charges (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Amortization of Deferred Charges for 12 consecutive years, with $446000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges fell 11.16% year-over-year to $446000.0, compared with a TTM value of $1.9 million through Dec 2025, down 10.96%, and an annual FY2025 reading of $1.9 million, down 10.96% over the prior year.
  • Amortization of Deferred Charges was $446000.0 for Q4 2025 at Tandem Diabetes Care, roughly flat from $444000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $702000.0 in Q3 2023 and bottomed at $428000.0 in Q1 2021.
  • Average Amortization of Deferred Charges over 5 years is $488800.0, with a median of $479000.0 recorded in 2023.
  • The sharpest move saw Amortization of Deferred Charges crashed 88.74% in 2021, then surged 40.68% in 2023.
  • Year by year, Amortization of Deferred Charges stood at $435000.0 in 2021, then grew by 15.17% to $501000.0 in 2022, then fell by 1.6% to $493000.0 in 2023, then rose by 1.83% to $502000.0 in 2024, then decreased by 11.16% to $446000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for TNDM at $446000.0 in Q4 2025, $444000.0 in Q3 2025, and $465000.0 in Q2 2025.